A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by John Ravits
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSD
- John Ravits
Professor Of Clinical, Neurosciences, Vc-health Sciences-schools. Authored (or co-authored) 108 research publications. Research interests: ALS neuroanatomic propagation · ALS molecular neuropathology · ALS genomics and transcriptome · C9orf72 ALS · Antisense oligonucleotide therapies · ALS clinical trials
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AL-S Pharma
- ID
- NCT05039099
- Phase
- Phase 2 Amyotropic Lateral Sclerosis (ALS) Research Study
- Study Type
- Interventional
- Participants
- Expecting 63 study participants
- Last Updated